Inositol Dosing for Conception and Pregnancy
For women trying to conceive with PCOS, use myo-inositol 4000 mg daily (2000 mg twice daily) combined with folic acid, and continue this same dose during pregnancy if supplementation is maintained.
Preconception Dosing (Trying to Conceive)
The evidence strongly supports myo-inositol 4000 mg daily (administered as 2000 mg twice daily) combined with folic acid for women with PCOS attempting conception 1, 2. This regimen has demonstrated:
- Restoration of ovulatory function in 88% of PCOS patients, with 72% maintaining normal ovulatory activity 1
- Pregnancy rates of 15-40% in women with PCOS-related infertility 1, 2
- Improved oocyte quality and better fertilization rates in women undergoing IVF 2
- Reduced FSH requirements during ovarian stimulation 2
Preconception Treatment Duration
- Begin supplementation 2-3 months before attempting conception or starting IVF protocols 2
- For women undergoing IVF, a minimum of 2 months pre-treatment is recommended before starting stimulation protocols 2
Important Preconception Considerations
The combination product typically contains myo-inositol 2000 mg + folic acid 200 mcg per dose, taken twice daily (total: 4000 mg myo-inositol + 400 mcg folic acid daily) 1, 2. This formulation addresses both ovulatory dysfunction and provides the recommended folic acid for neural tube defect prevention 3, 4.
Dosing During Pregnancy
Continue myo-inositol 4000 mg daily during pregnancy if supplementation is maintained, as this dose has been studied for pregnancy outcomes 5. The evidence supports:
- Primary prevention of gestational diabetes mellitus (GDM) with myo-inositol supplementation 5
- Reduction in macrosomia and neonatal hypoglycemia risk in mothers at risk for GDM 5
- Potential reduction in neural tube defects when myo-inositol is added preconceptionally to folic acid in women with previous NTD-affected pregnancies 5
Folic Acid Dosing Adjustments in Pregnancy
While myo-inositol dosing remains consistent, folic acid requirements change:
- Standard risk women: 400-800 mcg (0.4-0.8 mg) daily throughout pregnancy 3
- High-risk women (previous NTD, diabetes, certain medications): 4 mg daily until 12 weeks gestation, then reduce to 400 mcg (0.4 mg) for remainder of pregnancy 3
Key Clinical Considerations
Safety Profile
- No moderate to severe side effects reported at 4000 mg daily dosing 2
- No increased risk of multiple pregnancy compared to other ovulation induction agents 1
- The combination is considered safe throughout the preconception and pregnancy periods 1, 5, 2
Evidence Quality Caveat
While myo-inositol shows promising results, the Cochrane review notes that evidence quality is low to very low for live birth outcomes, with uncertainty remaining about definitive improvements in live birth rates when compared to standard treatment 6. However, the consistent improvements in ovulation, oocyte quality, and metabolic parameters across multiple studies support its use 1, 5, 2.
Practical Implementation
Do not use D-chiro-inositol (DCI) alone or in unspecified ratios, as more evidence is needed to establish optimal DCI dosing or definitive myo-inositol/DCI ratios 5. When combination products are used, a 3.6:1 myo-inositol to DCI ratio has shown preliminary positive results 7, though myo-inositol alone remains the most studied and recommended form 1, 5, 2.